The Fuyukang® series cover 158 genes related to targeted drugs, chemotherapy drugs and genetic risks. Using next-generation sequencing (NGS) technology of target gene capture, it comprehensively and accurately detects target gene capture exons and single nucleotide variations (SNV), short fragment insertion or deletion variations (InDel), gene copy number variations (CNV) and gene rearrangement/fusion within the intron range of standard spliceosomes, to provide reference and guidance for clinical medication and genetic risk of patients with gynecological tumors.
▪ Covers 52 genes related to targeted therapy of gynecological tumors that have been approved by FDA/NMPA, recommended in NCCN guidelines, or have shown clinically significant potential in clinical trials, and evaluates multiple targeted drugs for gynecological tumors that have been approved or in phase II/III clinical trials
▪ Covers 16 HRR genes. Combined with HRD score test, it comprehensively assesses HRD status and the efficacy of PARP inhibitors
▪ Covers 108 chemotherapy genes related to Asian/Chinese populations and assesses the efficacy and toxicity risks of chemotherapy drugs
▪ Covers the germline interpretation of 18 genes and prompts genetic risks
▪ The mutation information is accurately described according to the HGVS standard terms. The germline genetic mutations are classified according to the ACMG guidelines for the classification of the pathogenicity of mutations, and the clinical medication is suggested based on clinical based medical evidence
▪ Ultra-high depth sequencing and the limit of detection of ctDNA is 0.1%
Copyright©2021
Shenzhen yucebio Technology Co., Ltd. all rights reserved
Yueicp no.16128839
